Bdenza OS (enzalutamide oral solution) / BDR Pharma - LARVOL DELTA

Dr. Bilen on survival outcomes with apalutamide vs enzalutamide in mCSPC (Urology Times) - "In this video, Mehmet Asim Bilen, MD, discusses the background and key findings from the study, 'Real-world survival of men with metastatic castration-sensitive prostate cancer (mCSPC) initiated on apalutamide (APA) or enzalutamide (ENZ) in an oncology database: ROME Study...'"

Video

BDR Pharmaceuticals introduces prostate cancer treatment drug in oral solution form (Moneycontrol) - "BDR Pharmaceuticals on January 2 said it has introduced Enzalutamide oral solution for treatment of prostate cancer, claiming to be the first company in the world to bring it through the new drug delivery system. The company has introduced the Enzalutamide oral solution as BDENZA, in 32 mg/ml priced at Rs 27,000 for 150ml, BDR Pharmaceuticals said in a statement....The company said introducing the Drug Controller General of India (DCGI) approved new drug delivery system will make it more affordable and accessible in India."

Launch non-US • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor